R&D channel feed

Bio­haven turns out a dud in fa­tal neu­rode­gen­er­a­tive dis­ease, cast­ing doubt on drug's chances in ALS

4 years ago

Mer­ck touts a con­fir­ma­to­ry Keytru­da win for liv­er can­cer as 'dan­gling' ac­cel­er­at­ed ap­proval saga march­es on

4 years ago
Pharma

Days of heat­ed ru­mors cul­mi­nate in a re­port that Ac­celeron is in ad­vanced buy­out talks

4 years ago
Deals

Mi­cro­cap gene ther­a­py play­er says three chil­dren suf­fered se­ri­ous side ef­fects in PhI/II study

4 years ago
Cell/Gene Tx

As­traZeneca and Mer­ck hope new da­ta can PRO­pel their PARP in­hibitor in­to first-line prostate can­cer

4 years ago

As­traZeneca teams up with Im­pe­r­i­al off­shoot Vax­E­quity on an RNA 3.0 ef­fort

4 years ago
Deals

With world still in sore need of dos­es, Clover says its Covid-19 vac­cine is 67% ef­fec­tive in Phase III

4 years ago
Coronavirus

Ex­elix­is pulls a sur­prise win in thy­roid can­cer just days ahead of fi­nal Cabome­tyx read­out

4 years ago
FDA+

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

4 years ago
In Focus

Covid-19 roundup: In­dia to re­sume vac­cine ex­ports as its own cam­paign is un­der con­trol; Pfiz­er to file for vac­cine OK in chil­dren ages 5-11

4 years ago

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

4 years ago

The best of the rest: High­lights from the be­low-the-fold pre­sen­ta­tions at #ES­MO21

4 years ago

Mi­rati's KRAS drug looks like the ear­ly fa­vorite in colon can­cer with new da­ta, putting the pres­sure square on Am­gen

4 years ago

As­traZeneca, Dai­ichi Sanky­o's ADC En­her­tu blows away Roche's Kad­cy­la in sec­ond-line ad­vanced breast can­cer

4 years ago

Mer­ck flesh­es out Keytru­da win in first-line cer­vi­cal can­cer, adding more fire­pow­er to its ear­ly can­cer push

4 years ago

Mer­ck­'s Keytru­da un­corks full da­ta on lat­est ad­ju­vant win — this time in melanoma — adding bricks to ear­ly can­cer wall

4 years ago

EQRx, CStone un­furl full lung can­cer da­ta for PD-L1 drug in what the part­ners are call­ing a first

4 years ago

As­traZeneca touts Imfinzi im­munother­a­py com­bos for lung can­cer in push to dri­ve PD-L1 drug up­take

4 years ago

Gilead keeps push­ing trove of Trodelvy da­ta as it seeks to be­come new stan­dard of care in TNBC

4 years ago

The Ari­ad vets de­vel­op­ing next-gen TKIs are head­ing back to Nas­daq — and Or­biMed stands to reap the most

4 years ago
Financing

Who needs pri­ma­ry end­points any­way? Aerie touts sil­ver lin­ings from failed PhI­Ib, plots PhI­II in dry eye dis­ease

4 years ago

Zymeworks squares up with Her­ceptin af­ter HER2 bis­pe­cif­ic aces mid-stage test in esophageal can­cer

4 years ago

Am­gen rolls out da­ta for KRAS in­hibitor com­bo study in col­orec­tal can­cer, hop­ing to move on from ug­ly ear­ly re­sults

4 years ago

Ace­po­dia un­corks a very ear­ly win for its an­ti­body-nat­ur­al killer cell con­ju­gates in HER2 tu­mors

4 years ago
First page Previous page 158159160161162163164 Next page Last page
A service from the Financial Times